@MarioIannaccon8 Look at this summary 🤔 https://t.co/0ZTOAqRl5A https://t.co/MgD0sy9aBz
@jedicath @w_jyg @evandrofilhobr @KAlaswadMD @GreggWStone @Babar_Basir @KhandelwalMD @CMichaelGibson @MichaelMegalyMD @kjkunkelmd @AnkurGuptaMD https://t.co/9yjWIZx0mr What do you think about this study?
RT @BiotronikES: Un estudio liderado por el Dr. @Kandzari demuestra la seguridad y efectividad de nuestro stent farmacoactivo en sujetos co…
RT @BiotronikES: Un estudio liderado por el Dr. @Kandzari demuestra la seguridad y efectividad de nuestro stent farmacoactivo en sujetos co…
RT @BiotronikES: Un estudio liderado por el Dr. @Kandzari demuestra la seguridad y efectividad de nuestro stent farmacoactivo en sujetos co…
Un estudio liderado por el Dr. @Kandzari demuestra la seguridad y efectividad de nuestro stent farmacoactivo en sujetos con lesiones de la arteria coronaria https://t.co/knaVWLFg7r vía @JACCJournals https://t.co/Cxyz2HNXot
RT @JACCJournals: New in #JACCINT: Is BP SES (Orsiro) superior to DP EES (Xience)? Three year results of Bioflow V study showed lower TLF a…
RT @JACCJournals: New in #JACCINT: Is BP SES (Orsiro) superior to DP EES (Xience)? Three year results of Bioflow V study showed lower TLF a…
RT @JACCJournals: New in #JACCINT: Is BP SES (Orsiro) superior to DP EES (Xience)? Three year results of Bioflow V study showed lower TLF a…
@ISeropianMD
RT @JACCJournals: New in #JACCINT: Is BP SES (Orsiro) superior to DP EES (Xience)? Three year results of Bioflow V study showed lower TLF a…
New in #JACCINT: Is BP SES (Orsiro) superior to DP EES (Xience)? Three year results of Bioflow V study showed lower TLF and late/very late stent thrombosis with BP SES compared with DP EES. Learn more: https://t.co/FG9z8OYnO2 #Orsiro #Xience @Kandzari http
RT @JACCJournals: Bioflow V study from Dr. @Kandzari et al. shows the Orsiro stent is associated with lower target lesion failure and late/…
RT @JACCJournals: Bioflow V study from Dr. @Kandzari et al. shows the Orsiro stent is associated with lower target lesion failure and late/…
RT @JACCJournals: Bioflow V study from Dr. @Kandzari et al. shows the Orsiro stent is associated with lower target lesion failure and late/…
RT @JACCJournals: Bioflow V study from Dr. @Kandzari et al. shows the Orsiro stent is associated with lower target lesion failure and late/…
RT @JACCJournals: Bioflow V study from Dr. @Kandzari et al. shows the Orsiro stent is associated with lower target lesion failure and late/…
RT @JACCJournals: Bioflow V study from Dr. @Kandzari et al. shows the Orsiro stent is associated with lower target lesion failure and late/…
RT @JACCJournals: Bioflow V study from Dr. @Kandzari et al. shows the Orsiro stent is associated with lower target lesion failure and late/…
RT @JACCJournals: Bioflow V study from Dr. @Kandzari et al. shows the Orsiro stent is associated with lower target lesion failure and late/…
Bioflow V study from Dr. @Kandzari et al. shows the Orsiro stent is associated with lower target lesion failure and late/very late stent thrombosis at three years compared with the Xience stent. https://t.co/FG9z8OYnO2 #JACCINT https://t.co/AN5r5kkROW
Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization | JACC: Cardiovascular Interventions https://t.co/5iPw5TygEC
RT @JACCJournals: #JACCINT Editor Dr. Moliterno interviews Dr. @Kandzari about 3-year BIOFLOW-V #CRT2020 late-breaking results showing sign…
RT @JACCJournals: #JACCINT Editor Dr. Moliterno interviews Dr. @Kandzari about 3-year BIOFLOW-V #CRT2020 late-breaking results showing sign…
RT @JACCJournals: #JACCINT Editor Dr. Moliterno interviews Dr. @Kandzari about 3-year BIOFLOW-V #CRT2020 late-breaking results showing sign…
RT @KardiologieHH: Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents versus Thin Durable Polymer Everolimus-Eluting Stents for Coron…
RT @KardiologieHH: Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents versus Thin Durable Polymer Everolimus-Eluting Stents for Coron…
Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents versus Thin Durable Polymer Everolimus-Eluting Stents for Coronary Revascularization: Three-year Outcomes from the Randomized BIOFLOW V Trial @AGIKinterv @KPujdak @kaschenke https://t.co/yvsCRy8Dvl
RT @JACCJournals: #JACCINT Editor Dr. Moliterno interviews Dr. @Kandzari about 3-year BIOFLOW-V #CRT2020 late-breaking results showing sign…